Drugs / SYH2053
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06229548 | Jan → Dec 2024 | hyperlipidemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07421232 | Dec 2024 → Aug 2025 | hyperlipidemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT07421284 | Mar 2026 → Dec 2027 expected | hyperlipoproteinemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07465263 | Mar 2026 → Feb 2028 expected | familial hypercholesterolemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07421297 | Feb 2026 → Dec 2027 expected | hyperlipoproteinemia | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-11-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-11-30 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - SYH2053 INJECTION (siRNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2053 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07421232 ↗ |
| Route | Subcutaneous | “Subjects in SAD experimental groups will receive a single subcutaneous injection of SYH2053 on Day 1.” NCT06229548 ↗ |